Free Trial
NASDAQ:ATHA

Athira Pharma Q1 2024 Earnings Report

Athira Pharma logo
$4.16 -0.05 (-1.19%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Athira Pharma EPS Results

Actual EPS
-$6.90
Consensus EPS
-$8.00
Beat/Miss
Beat by +$1.10
One Year Ago EPS
N/A

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Announcement Details

Quarter
Q1 2024
Time
After Market Closes
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Athira Pharma's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Athira Pharma Earnings Headlines

Athira Pharma (NASDAQ:ATHA) Stock Price Up 9.1% - What's Next?
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
Athira Pharma trading halted, news pending
Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:ATHA) is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system. Fosgonimeton has advanced through Phase 1 and Phase 2 clinical trials, where it has been evaluated for safety, tolerability and preliminary efficacy in patients with mild to moderate Alzheimer’s disease and other forms of cognitive impairment. In addition to ATH‐1017, the company is exploring follow‐on small‐molecule candidates designed to target related pathways and broaden the potential therapeutic impact across multiple neurodegenerative indications.

Athira Pharma went public in 2019 and is traded on the Nasdaq under the symbol ATHA. The company conducts clinical studies in the United States and Europe in collaboration with academic research centers and contract research organizations. Leadership has included key figures from both the biotech and neuroscience research communities, with a management team experienced in drug development, clinical operations and regulatory affairs. Athira continues to engage with strategic partners to support its mission of bringing novel, disease‐modifying treatments to patients suffering from progressive neurological disorders.

View Athira Pharma Profile

More Earnings Resources from MarketBeat